BOEHRINGER-INGELHEIM
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sine digitale transformationskompetencer med MOYO23.10.2025 19:47:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at styrke sine transformationskompetencer inden for teknologi og forretning via en samarbejdsaftale med MOYO, der er et digitalt konsulenthus, som leverer integrerede løsninger inden for strategi, data, teknologi, programmering og talentudvikling. MOYO, der blev grundlagt i 2007 af administrerende direktør Pierre le Roux, kombinerer tjenester inden for rådgivning, teknologi og humankapital-tjenester for at hjælpe en bred kundebase – fra startups til store virksomheder inden for finansielle tjenester, minedrift og detailhandel – med at implementere skalerbare systemer, optimere processer og levere skræddersyede løsninger, der udnytter nye muligheder i den digitale økonomi. "Hos MOYO mener vi, at digital transformation kun lykkes, når løsninger skabes med dyb empati og en klar forståelse for menneskene bag virksomheden," sagde Pierre. "Vores samarbejde med Andersen Consulting afspejler det samme engagement i at skabe meningsfulde, langsigtede forandring
Berry Consultants Releases FACTS 8 Clinical Trial Simulator23.10.2025 19:00:00 CEST | Press release
FACTS 8 introduces support for Ordinal endpoints and a new “Quick Start” feature Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/ FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements: Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis. A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provide
Saudi Arabia to Host 26th UN Tourism General Assembly in November Marking Agency’s 50th Year23.10.2025 16:58:00 CEST | Press release
The Kingdom of Saudi Arabia will host the 26th session of the UN Tourism General Assembly from November 7 to 11. The landmark session will focus on “AI-Powered Tourism: Redefining the Future” and also commemorate five decades of cooperation under the United Nations’ specialized agency for tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022579574/en/ Riyadh Nighttime View Represented by its Ministry of Tourism, Saudi Arabia will welcome more than 160 member states, international organizations, and global industry players to engage in dialogue aimed at securing a brighter, more sustainable future for the industry and shaping the next 50 years of global tourism. Saudi Arabia’s Minister of Tourism, H.E. Ahmed Al Khateeb, invited the world to Riyadh to take part in a momentous milestone for global tourism diplomacy: “We look forward to hosting the world’s leading organization for tourism in a session that will redefine
Macrobond and FactSet Collaborate to Deliver Direct Access to Global Equity Data on a Single Integrated Research Platform23.10.2025 15:49:00 CEST | Press release
This integration brings FactSet’s market-leading fundamentals, estimates, and ETF data directly into Macrobond’s intuitive platform. Macrobond, the leading provider of global economic and financial data and analytics, today announced a strategic integration with FactSet, a global digital platform and enterprise solutions provider. This collaboration provides Macrobond users with direct access to FactSet’s extensive equity and ETF datasets—including fundamentals, consensus estimates, market aggregates, and equity prices and returns —within the Macrobond platform. By combining Macrobond’s top-down macroeconomic insights with FactSet’s bottom-up company analysis, this collaboration delivers a uniquely complementary dataset that empowers clients to seamlessly integrate global economic trends with detailed security-level intelligence. This integration creates a seamless environment for economists, strategists, and analysts to analyze equity data with the efficiency and precision that define
Wolters Kluwer Ranks First in Dresner 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting Market Study23.10.2025 15:30:00 CEST | Press release
Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that its CCH® Tagetik Intelligent Platform has achieved the top position in the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This marks the second straight year that Wolters Kluwer has earned the study’s number one ranking. Access the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This study is part of Dresner Advisory Services’ ongoing research into the enterprise performance management (EPM) space and focuses specifically on performance management capabilities targeted at the finance function, including financial consolidation, close management and financial reporting. The study also identifies user trends, priorities, adoption patterns, and vendor performance, helping organizations make informed de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom